Grant: CIHR Fellowship
University of Toronto
$135,000.00
Preclinical Development of Small Molecule HDAC6 Degraders in Peripheral T-cell Lymphoma and Leukemia
FY 2023-24
Summary
Peripheral T-cell lymphomas (PTCLs) refer to a diverse group of rare but aggressive mature T-cell lymphomas/leukemias. PTCLs are mostly aggressive and incurable cancers with poor median survival times of ~20 months. These patients are additionally exposed to poor treatment options, which result in severe side effects that influence their quality of life. Recent studies have revealed emerging roles for the protein, Histone Deacetylase 6 (HDAC6), in PTCL. HDAC6 is the largest HDAC isoform, from a family of 11 HDAC proteins. Moreover, the roles of HDAC6 extend beyond the conventional enzymatic/deacetylase functions, but also include a range of indispensable protein-protein interactions with key cancer oncodrivers such as STAT3. These interactions have shown to be necessary for progression of several T Cell cancers. Due to these non-canonical functions, the four clinically approved HDAC drugs have failed to long-term induce therapeutic utility in T-cell patients. Here we are developing a paradigm shifting therapeutic technology to selectively target and efficient degrade HDAC6, thereby abolishing all enzymatic and non-enzymatic functions of the protein. The aim of this research program to advance lead preclinical drug candidates that can disrupt and/or degrade key protein interactions (such as HDAC6-STAT3) in PTCL cell lines and can therefore arrest tumor growth. During this proposed study, molecules will be synthesized based on the current lead candidate, TO-1187, and will be evaluated for target engagement and efficacy in inhibiting tumor growth in cell line and mouse xenograft models. The most promising candidates will be advanced for advanced pre-clinical trials and IND-enabling studies to ultimately benefiting the therapy of PTCL patients.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
492454
Name
Pölöske Daniel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Preclinical Development of Small Molecule HDAC6 Degraders in Peripheral T-cell Lymphoma and Leukemia
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Drug Discovery; Histone Deacetylase; Medicinal Chemistry; Small Molecular Degrader; T Cell Cancer
Abstract
Peripheral T-cell lymphomas (PTCLs) refer to a diverse group of rare but aggressive mature T-cell lymphomas/leukemias. PTCLs are mostly aggressive and incurable cancers with poor median survival times of ~20 months. These patients are additionally exposed to poor treatment options, which result in severe side effects that influence their quality of life. Recent studies have revealed emerging roles for the protein, Histone Deacetylase 6 (HDAC6), in PTCL. HDAC6 is the largest HDAC isoform, from a family of 11 HDAC proteins. Moreover, the roles of HDAC6 extend beyond the conventional enzymatic/deacetylase functions, but also include a range of indispensable protein-protein interactions with key cancer oncodrivers such as STAT3. These interactions have shown to be necessary for progression of several T Cell cancers. Due to these non-canonical functions, the four clinically approved HDAC drugs have failed to long-term induce therapeutic utility in T-cell patients. Here we are developing a paradigm shifting therapeutic technology to selectively target and efficient degrade HDAC6, thereby abolishing all enzymatic and non-enzymatic functions of the protein. The aim of this research program to advance lead preclinical drug candidates that can disrupt and/or degrade key protein interactions (such as HDAC6-STAT3) in PTCL cell lines and can therefore arrest tumor growth. During this proposed study, molecules will be synthesized based on the current lead candidate, TO-1187, and will be evaluated for target engagement and efficacy in inhibiting tumor growth in cell line and mouse xenograft models. The most promising candidates will be advanced for advanced pre-clinical trials and IND-enabling studies to ultimately benefiting the therapy of PTCL patients.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Pölöske, Daniel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~